Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and albumin. He compares and contrasts it to key competitor BIMZELX and describes what the company is hoping to see in the trial readout. Plus, commercial plans, pipeline, and more.